MedTrace Logo

DOuBLED - Doubling Outcomes by Lung Cancer Early Diagnosis

NCT05091437 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 562

Last updated 2025-09-24

No results posted yet for this study

Summary

Early diagnosis of LC in the asymptomatic stage through intentional screening programs and/or incidental pulmonary nodule identification and follow-up are known to improve outcomes significantly. There are large gaps in the screening and early detection of LC, especially in LMIC - driven by multifactorial aspects, including a variety of socioeconomic and infrastructural factors, mainly due to limitations in the required network of specialized human resources and technical capacity. Identifying LC at an early stage allows for treatment that is more likely to be curative, thereby improving survival.

The present study aims to characterize the lung nodule journey in different hospitals/clinics across Latin America, describing the use of health resources, time to diagnosis, stage at diagnosis, and time to treatment depending on the source of nodule identification in two different cohorts (retrospective and prospective).

Conditions

  • Pulmonary Nodules

Interventions

DIAGNOSTIC_TEST

Observational study

Incidental lung nodules identification

Sponsors & Collaborators

  • INCUNA (Scientific and Technical partner)

    collaborator UNKNOWN

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Larisa Ramirez, MD · AstraZeneca

Eligibility

Min Age
35 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-30
Primary Completion
2024-11-30
Completion
2024-11-30

Countries

  • Argentina
  • Brazil
  • Chile
  • Colombia
  • Costa Rica
  • Dominican Republic
  • Mexico
  • Panama

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05091437 on ClinicalTrials.gov